CRO, the innovative drug sector, started to rise at the opening, with Menova hitting the limit up.

The CRO and innovative drug sector rose at the beginning of the session, with Minohua hitting the limit up, Jinkai Shengke up over 10%, and Baiose Graph, Baihua Pharmaceutical, Ruizhi Pharmaceutical, Hait Bio, and Pharmaron all following the upward trend. In terms of related ETFs, the biopharmaceutical ETF managed by Fusheng Fu rose by 1.85%, with a turnover of 11.5967 million yuan, while the vaccine ETF managed by Jiashi rose by 1.27%, with a turnover of 1.5814 million yuan.